CTCs As a Prognostic and Predictive Biomarker for Stage II/III Colon Cancer: a Companion Study to the PePiTA Trial

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Apr 5

PMID 30943928

Citations 8

Authors

Francoise Rothe

Marion Maetens

Ghizlane Rouas

Marianne Paesmans

Marc Van den Eynde

Jean-Luc Van Laethem

Philippe Vergauwe

Guido Deboever

Yacine Bareche

Caroline Vandeputte

Michail Ignatiadis

Alain Hendlisz

Affiliations

Soon will be listed here.

Abstract

Background: Adjuvant therapy improves the prognosis of stage II & III colon cancer patients. Unfortunately, most patients do not benefit from this treatment. PePITA (NCT00994864) is a prospective, multicenter, non-randomized study whose primary objective is to predict the outcome of adjuvant therapy in colon cancer.

Methods: The primary objective was to determine the prognostic and predictive value of circulating tumor cell (CTC) detection before therapy and after one course of preoperative FOLFOX.

Results: Out of the 58 first patients accrued in PePiTA trial, 36 patients participated in the CTC companion study, of whom 32 had at least one evaluable sample. Only 5 patients (14, 95% CI = 5-30%) had ≥1 CTC/22.5 ml blood in at least one of the two timepoints with 2 patients having ≥1 CTC/22.5 ml at baseline (6, 95% CI: 1-19%). The detection rate of patients with CTCs at baseline being lower than expected, the inclusion of patients in the PePiTA CTC substudy was stopped. The limited sample size did not allow us to investigate the prognostic and predictive value of CTCs in locally advanced colon cancer.

Conclusions: Our data illustrate the need for further standardized studies in order to find the most reliable prognostic/predictive biomarker in early-stage colon cancer.

Trial Registration: This trial was prospectively registered at Jules Bordet institute ( NCT00994864 ) on the October 14, 2009.

Citing Articles

Plasma proteomic characterization of colorectal cancer patients with FOLFOX chemotherapy by integrated proteomics technology.

Wang X, Zhang K, He W, Zhang L, Gao B, Tian R Clin Proteomics. 2024; 21(1):27.

PMID: 38580967 PMC: 10998366. DOI: 10.1186/s12014-024-09454-z.

MiSelect R System: the validation of a new detection system of CTCs and their correlation with prognosis in non-metastatic CRC patients.

Lin C, Yang C, Hung T, Wang C, Wei S, Schiro P Sci Rep. 2023; 13(1):4773.

PMID: 36959311 PMC: 10036555. DOI: 10.1038/s41598-023-31346-9.

Efficacy of jianpi huatan granule in reducing colorectal cancer metastasis and recurrence after radical resection and adjuvant chemotherapy: Study protocol for a randomised, double-blind, placebo-controlled, multicentre trial.

Li L, Qu Q, Cui N, Cai L, Zou J, Wu J Front Pharmacol. 2022; 13:944475.

PMID: 36176445 PMC: 9513522. DOI: 10.3389/fphar.2022.944475.

Utility of circulating tumor cells in stage II colorectal cancer patients undergoing curative resection.

Yu J, Wang D, Jin L, Wang J, Zhao X, Wu G Transl Cancer Res. 2022; 9(3):1487-1494.

PMID: 35117496 PMC: 8798397. DOI: 10.21037/tcr.2020.01.37.

Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells.

Tieng F, Abu N, Nasir S, Lee L, Mutalib N Diagnostics (Basel). 2021; 11(11).

PMID: 34829483 PMC: 8618170. DOI: 10.3390/diagnostics11112136.

References

Vogel I, Kalthoff H . Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch. 2001; 439(2):109-17. DOI: 10.1007/s004280100476. View

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D . Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002; 8(7):2073-84. View

Palmieri G, Ascierto P, Perrone F, Satriano S, Ottaiano A, Daponte A . Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol. 2003; 21(5):767-73. DOI: 10.1200/JCO.2003.01.128. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Chen W, Chung M, Liu J, Liu J, Lin J . Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery. World J Surg. 2004; 28(6):552-7. DOI: 10.1007/s00268-004-7276-9. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Cristofanilli M, Hayes D, Budd G, Ellis M, Stopeck A, Reuben J . Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. DOI: 10.1200/JCO.2005.08.140. View

Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C . Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006; 118(12):3072-7. DOI: 10.1002/ijc.21784. View

10.

Lloyd J, McIver C, Stephenson S, Hewett P, Rieger N, Hardingham J . Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res. 2006; 12(2):417-23. DOI: 10.1158/1078-0432.CCR-05-1473. View

11.

Allen-Mersh T, McCullough T, Patel H, Wharton R, Glover C, Jonas S . Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg. 2006; 94(1):96-105. DOI: 10.1002/bjs.5526. View

12.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

13.

Uen Y, Lu C, Tsai H, Yu F, Huang M, Cheng T . Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol. 2008; 15(8):2120-8. DOI: 10.1245/s10434-008-9961-7. View

14.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

15.

Pierga J, Bidard F, Mathiot C, Brain E, Delaloge S, Giachetti S . Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008; 14(21):7004-10. DOI: 10.1158/1078-0432.CCR-08-0030. View

16.

Tsouma A, Aggeli C, Pissimissis N, Lembessis P, Zografos G, Koutsilieris M . Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res. 2009; 28(6B):3945-60. View

17.

Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H . Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27(10):1549-56. DOI: 10.1200/JCO.2008.17.0563. View

18.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20(7):1223-9. DOI: 10.1093/annonc/mdn786. View

19.

Liu M, Shields P, Warren R, Cohen P, Wilkinson M, Ottaviano Y . Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009; 27(31):5153-9. PMC: 4879719. DOI: 10.1200/JCO.2008.20.6664. View

20.

Tol J, Koopman M, Miller M, Tibbe A, Cats A, Creemers G . Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2009; 21(5):1006-12. DOI: 10.1093/annonc/mdp463. View